MeiraGTx Announces FDA Breakthrough Therapy Designation for AAV2-hAQP1 for the Treatment of Grade 2 and Grade 3 Radiation-Induced Xerostomia (RIX) and Reports Fourth Quarter and Full Year 2025 Financi

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/22/2026

1. SPCX
2. NVDA
3. ACN
4. USO
5. APGE
6. HOOD
7. DFTX
8. GOOGL
9. MU
10. IBM

Go back to MeiraGTx Announces FDA Breakthrough Therapy Designation for AAV2-hAQP1 for the Treatment of Grade 2 and Grade 3 Radiation-Induced Xerostomia (RIX) and Reports Fourth Quarter and Full Year 2025 Financi
(NASDAQ: MGTX) Delayed: 11.48 +0.16 (1.41%)
Previous Close $11.32    52 Week High $ 
Open $11.48    52 Week Low $ 
Day High $11.81    P/E N/A 
Day Low $11.18    EPS $ 
Volume 1,292,750       

(NASDAQ: MGTX) Delayed: 11.48 +0.16 (1.41%)
Previous Close $11.32    52 Week High $ 
Open $11.48    52 Week Low $ 
Day High $11.81    P/E N/A 
Day Low $11.18    EPS $ 
Volume 1,292,750